Top View
- Chemotherapy Drugs
- A Thesis Entitled Metal Binding Characteristics of Heterocyclic and Carbocyclic Anticancer Drugs by Brittany Bezoski Submitted T
- A12-17 Pixantrone – Benefit Assessment According 1 to § 35A Social Code Book V
- Recent Advances in the Management of Hematologic Malignancies
- Chemotherapy Drugs
- Liste Des Molécules
- Policy for the Management of Extravasation
- System-Level Analysis of Neuroblastoma Tumor–Initiating Cells Implicates AURKB As a Novel Drug Target for Neuroblastoma
- Targeting Endothelial Cell Metabolism for Cardio-Protection from the Toxicity of Antitumor Agents Lucia Morbidelli*, Sandra Donnini and Marina Ziche
- Pixantrone for the Treatment of Adult Patients with Relapsed Or Refractory Aggressive Non-Hodgkin B-Cell Lymphomas
- EMETOGENICITY of CHEMOTHERAPY REGIMENS Version 2019
- Complete Response to Pixantrone As a Salvage Therapy in a Relapsed
- Is the European Pediatric Medicine Regulation Working for Children and Adolescents with Cancer?
- GUIDELINE for MANAGEMENT of EXTRAVASATION Extravasation Is a Severe Complication in the Administration of Cytotoxic Chemotherapy
- PIXUVRI, INN-Pixantrone
- Liste Des Molécules
- Clinical Evidence for the Role of Pixantrone in the Treatment of Relapsed Or Refractory Aggressive Non-Hodgkin’S Lymphoma
- Pixantrone, a New Anticancer Drug with the Same Old Cardiac Problems? an in Vitro Study with Differentiated and Non-Differentiated H9c2 Cells
- Guidelines on Treatment of Extravasation with Cytotoxic Drugs
- Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
- Pixantrone Monotherapy for Treating Multiply Relapsed Or Refractory Aggressive Non-Hodgkin's B-Cell Lymphoma
- Application of Pixantrone in a Iii Line of Treatment As a Bridge Therapy To
- Research in Your Backyard Developing Cures, Creating Jobs
- Chemotherapy Drugs
- Hematology Drugs in the Pipeline
- Drug Development: Portals of Discovery
- Emetic Risk of Single Intravenous Antineoplastic Agents in Adults
- CTI Corporate Presentation
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- CELL THERAPEUTICS, INC. (Exact Name of Registrant As Specified in Its Charter)
- An Open Access Database of Licensed Cancer Drugs Pan Pantziarka 1,2, §, Rica Capistrano 1, Arno De Potter 3, Liese Vandeborne 1, Gauthier Bouche 1
- Single-Agent Pixantrone As a Bridge to Autologous Stem Cell Transplantation in a Patient with Refractory Diffuse Large B-Cell Lymphoma
- Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase Iia Isoform S
- Oncologic Drugs Advisory Committee Recommendations and Approval of Cancer Drugs by the US Food and Drug Administration
- NCCP Regimen Information Summary - by Drug Last Updated: 08/12/2020
- Filed by Cell Therapeutics, Inc. Pursuant to Rule 425 Under the Securities Act of 1933 Subject Company: Cell Therapeutics, Inc
- Management Chemotherapy and Radiotherapy Induced Nausea and Vomiting
- Adis R&D Insight
- Non Hodgkin's Lymphoma (Relapsed Refractory)
- Renal Impairment Hepatic Impairment Agent PK Summary Available
- CHMP Assessment Report
- NCCP Extravasation Classification of Systemic Anti-Cancer Therapy
- Filed by Cell Therapeutics, Inc. Pursuant to Rule 425 Under The
- Pharmacy Medical Necessity Guidelines: Anti-Emetic Medications
- PTJA06 – MAH Core Submission Dossier